Overview

Recent News

Date	Title and Summary
Toggle Summary Mar 06, 2019	Assertio Therapeutics Announces Fourth-Quarter and Full-Year 2018 Financial Results -- Reports Neurology Franchise Annual Net Sales of $110.3 million , at the High End of Guidance Range -- -- Files NDA for Long-Acting Cosyntropin and Receives FDA Notification of Acceptance -- -- Issues Full-Year 2019 Guidance for Earnings and Neurology Franchise Net Sales -- LAKE FOREST, Ill.
Toggle Summary Feb 21, 2019	Assertio Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results After The Close of Markets on Wednesday, March 6, 2019 LAKE FOREST, Ill. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that it will release fourth quarter and full year 2018 financial results on Wednesday, March 6, 2019 , after the close of markets. Following the announcement, the Company will host a
Toggle Summary Feb 19, 2019	Assertio Therapeutics Announces FDA Notification of Acceptance for Filing of 505(b)(2) NDA for Long-acting Cosyntropin Company Anticipates Potential Market Launch by Early 2020 LAKE FOREST, Ill. , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) announced today that it has received notification of acceptance for filing from the U.S. Food and Drug Administration ( FDA ) for its 505(b)(2)

Filing date	Description	Form	Filing Group	View
Aug 15, 2018	8-K12B	8-K12B	Other	View HTML 0001104659-18-052087.pdf 0001104659-18-052087.rtf 0001104659-18-052087.xls
Mar 29, 2002	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	Proxy Filings	View HTML 0000912057-02-012655.pdf 0000912057-02-012655.rtf 0000912057-02-012655.xls
Mar 25, 2015	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	Proxy Filings	View HTML 0001047469-15-002712.pdf 0001047469-15-002712.rtf 0001047469-15-002712.xls
Apr 05, 2016	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	Proxy Filings	View HTML 0001047469-16-011902.pdf 0001047469-16-011902.rtf 0001047469-16-011902.xls
Mar 16, 2018	A preliminary proxy statement providing notification matters to be brought to a vote	PRE 14A	Proxy Filings	View HTML 0001047469-18-001778.pdf 0001047469-18-001778.rtf 0001047469-18-001778.xls

Continental Stock Transfer & Trust Company
17 Battery Place, 8th Floor
New York, NY 10004
Phone: 800.509.5586
http://www.continentalstock.com

Ernst & Young LLP
Palo Alto, CA

John B. Thomas
SVP, Investor Relations & Corporate Communications
jthomas@assertiotx.com